Turanabol Tablets

Turinabol: The 4-Chloro Structure That Changed Oral Anabolic Pharmacology

Turanabol Tablets by British Dragon contain 4-Chlorodehydromethyltestosterone at 10 mg per tablet — the oral anabolic compound developed by East German pharmaceutical company Jenapharm in the early 1960s through a single structural modification to Methandrostenolone (Dianabol). The modification is a chlorine atom substituted at the C4 position of the steroid ring. This one change eliminates the compound's aromatase affinity entirely: Turinabol cannot convert to estrogen at any dose.

The same 4-chloro substitution also substantially reduces the compound's androgenic activity — DHT conversion is blocked by the same steric effect — producing a compound with a markedly more favorable anabolic:androgenic ratio than its Dianabol structural origin suggests. The result is an oral anabolic with genuine lean mass and strength output, a clean aesthetic profile, minimal androgenic side effects, and the complete absence of estrogen management requirements that Methanabol demands from the first week of use. The Turinabol vs Methanabol comparison covers these distinctions in full.

The East German Pharmaceutical History

Turinabol's development and use constitutes the most extensively documented institutionalised doping program in the history of competitive sport. Jenapharm developed the compound as a prescription therapeutic for muscle wasting and bone density in the early 1960s — legitimate pharmaceutical research. The East German Ministry of State Security (Stasi) and sports science infrastructure subsequently adapted Turinabol as the cornerstone of Staatsplanthema 14.25, a state-directed program administering performance-enhancing drugs to elite athletes from the 1970s through German reunification in 1990.

The program's scale was systematic: athletes were administered Turinabol through standardised protocols managed by sports physicians, often without the athletes' knowledge or meaningful informed consent, timed against competition schedules around the conventional detection windows available at the time. East German athletes during this period dominated international competition across track and field, swimming, rowing, and strength sports with a consistency that post-reunification investigations and athlete testimonies ultimately attributed to the systematic doping program.

The detection chemistry developed in subsequent decades dramatically extended the window beyond what the 1970s–80s testing infrastructure could identify. Modern IRMS (isotope ratio mass spectrometry) analysis, introduced into WADA-accredited laboratory protocols from the 2000s onward, detects Turinabol-specific metabolites at trace concentrations far beyond the historical 5–6 week window. This methodological advancement led to retrospective retesting of archived Olympic samples, resulting in numerous disqualifications and medal redistributions decades after the original competitions.

Turinabol vs Methanabol — The Architectural Distinction

Turinabol is structurally derived from Methandrostenolone (Methanabol) and shares its 17α-alkylation, its oral bioavailability, and its general anabolic character. The differences that the 4-chloro substitution produces are operationally fundamental:

• Aromatization: Methanabol aromatizes significantly — heavy water retention, active estrogen management required from week one, AI is standard protocol. Turinabol: zero aromatization at any dose. No AI required for Turinabol itself (AI may still be needed for co-administered aromatizing injectables)
• Mass character: Methanabol produces rapid, dramatic early mass increases — largely water — alongside lean mass, with significant weight loss post-cycle as estrogen normalises and fluid balance corrects. Turinabol produces slower, leaner mass gains with near-complete post-cycle retention because there is no estrogenic water component to lose
• Androgenic intensity: Methanabol has moderate androgenic activity and meaningful DHT conversion — acne, sebaceous activity, and hair loss acceleration are common at standard doses. Turinabol's androgenic rating is approximately 6 relative to testosterone's 100 — substantially lower androgenic side effect burden
• Strength increase timeline: Methanabol's strength increase is explosive in weeks 1–3 driven by both the direct anabolic effect and the volumising effect of water retention on muscle cell osmotic pressure. Turinabol's strength increase is more gradual and reflects genuine neuromuscular adaptation and lean tissue change rather than the partial strength contribution of fluid volume
• Dose required for equivalent lean output: Equivalent lean mass and strength gain from Turinabol versus Methanabol requires a higher Turinabol dose — 40–60 mg/day of Turinabol produces approximately the lean tissue equivalent of 20–30 mg/day of Methanabol, with the Methanabol generating substantially more total scale mass through water retention alongside that lean component

Dosing Protocol for Turanabol Tablets 10 mg

• Entry-level dose (20–30 mg/day): 2–3 tablets daily in split doses (morning and evening). Produces perceptible strength and lean mass increases with the lowest hepatic burden and most conservative androgenic profile. Used by first-time Turinabol users and female athletes at the lower end (10–20 mg/day). 100 tablets at 20 mg/day provides a 50-day supply.
• Standard performance dose (40–60 mg/day): 4–6 tablets daily in split doses. The productive range for lean mass and strength development in male athletes. At 40 mg/day, 100 tablets provides 25 days — plan two packs for a complete 6-week cycle at this dose.
• Advanced dose (60–80 mg/day): 6–8 tablets daily, split into two or three doses across the day. Applied to experienced athletes seeking maximum Turinabol output. The dose-response benefit above 80 mg/day is diminishing relative to increasing hepatic burden. Cycle length at advanced doses: 4–6 weeks maximum.
• Dosing split rationale: The ~16-hour half-life supports a twice-daily split (morning and early evening). This maintains more stable plasma levels than a single daily dose and reduces peak hepatic load versus the equivalent once-daily administration. Athletes who prefer the convenience of once-daily dosing typically take the full dose with the morning meal.
• Cycle length: 6–8 weeks as a standalone oral cycle; 4–6 weeks as an injectable cycle kickstart. Hepatic stress accumulates with cycle duration — 8 weeks is a practical maximum for 17α-alkylated oral administration regardless of dose.

Most Effective Stacks with Turanabol Tablets

• Turanabol Tablets solo (40–60 mg/day, 6–8 weeks) — the oral-only lean cycle for athletes making a first commitment to anabolic pharmacology or returning from a period of no cycle. Turinabol is one of a small number of oral compounds that produces genuinely meaningful lean mass and strength output without injectable testosterone support — its low androgenicity and zero estrogenic activity mean the physiological environment remains relatively balanced, producing lean mass gains that are fully retained post-cycle. See the Anavar vs Turinabol guide for a comparison of the two primary oral-only options.
• Turanabol Tablets (50 mg/day, throughout) + Testabol Propionate (400 mg/week EOD) — the lean short-cycle combination with matched clearance windows. Testosterone Propionate provides the mandatory androgenic base, libido maintenance, and hormonal foundation that Turinabol cannot substitute. Turinabol adds its SHBG-suppressing, lean-mass-building, strength-enhancing oral contribution throughout the cycle without adding any estrogenic activity or androgenic excess to the stack.
• Turanabol Tablets (60 mg/day, weeks 1–6 kickstart) + Decabol 250 (400 mg/week) + Testabol Enanthate (400 mg/week) — the dry kickstart covering a Nandrolone Decanoate base cycle. Both Decabol 250 and Testabol Enanthate are long-ester injectables with 3–4 week loading phases — 6 weeks elapse before either compound reaches full steady-state plasma levels. A Turinabol kickstart covers this loading window without adding estrogenic activity — a dry kickstart that does not require additional AI management beyond what the injectable base already demands.

Side Effects, Hepatotoxicity, and the Detection Consideration

• Hepatotoxicity: Turinabol is 17α-alkylated — this modification that confers oral bioavailability also produces liver enzyme elevation (ALT, AST) at standard doses. Active liver support throughout the cycle is not optional: TUDCA at 500 mg/day and NAC at 600 mg/day are the standard protocol. Cycle lengths beyond 8 weeks at standard doses and beyond 6 weeks at advanced doses produce progressively increasing hepatic burden without proportional additional lean mass benefit.
• Androgenic side effects: Substantially lower than testosterone-based compounds. Acne and sebaceous activity are reported at higher doses but are typically mild. Hair loss acceleration is not a significant concern at the compound's low androgenic rating. The low androgenic profile is what makes Turinabol one of the few orals used cautiously in female performance pharmacology at 10–20 mg/day — acknowledging that any exogenous androgen carries virilization risk and requires monitoring.
• HPTA suppression: Present at standard performance doses. Endogenous testosterone production suppresses within the first 2–3 weeks. Standard two-SERM PCT applies post-cycle.
• Detection time — the expanded window: Athletes subject to anti-doping analysis should be aware that the historically cited 5–6 week detection window for Turinabol does not reflect modern IRMS capability. Long-term metabolites — particularly the glucuronide conjugates of the compound's hydroxylated metabolites — have been detected via IRMS analysis at 4 months or more post-administration in some cases. The retrospective re-analysis of archived samples from multiple Olympic Games confirmed detections extending well beyond the periods athletes believed they were safe from testing.

Conclusion

Turanabol Tablets by British Dragon deliver 4-Chlorodehydromethyltestosterone — the compound that structured performance pharmacology's understanding of what a clean oral anabolic looks like. Zero aromatization, zero water retention, lean and fully-retained mass gains, low androgenicity, and genuine strength output define a profile that no other oral compound in this catalog replicates.

As a standalone entry-level oral cycle, a Methanabol-free injectable kickstart, a lean cutting oral base, or an SHBG-suppressing cycle enhancer, Turinabol occupies a pharmacological position no other compound in this lineup fills: the dry oral anabolic with a confirmed decades-long track record, documented across the most extensively studied institutional doping program in the history of competitive sport, now available at the precise 10 mg tablet dose that allows experienced athletes to calibrate dosing with precision across entry-level, standard, and advanced protocols.